Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Tests for Visceral Leishmaniasis Reviewed

By LabMedica International staff writers
Posted on 30 Jun 2014
The effectiveness of rapid diagnostic tests (RDTs) in diagnosing patients with visceral leishmaniasis (VL) has been reviewed by an independent expert group.

VL is caused by a parasite and results in fever, a large spleen and other health problems and diagnosis is extremely important as without treatment it can be fatal and proper treatment can result in a cure. More...


Scientists from the Cochrane Infectious Disease Group, coordinated through the editorial base in Liverpool School of Tropical Medicine (UK) found 24 studies, which contained information about five different RDTs, with a total of 4,271 participants. They describe how accurate these rapid diagnostic tests are for diagnosing VL in people who, according to their physicians, could have the disease. Only studies in which the investigators had used established methods to distinguish the people with VL from those who did not have the disease were used in the review.

One RDT, the rK39 immunochromatographic test (ICT) gave correct, positive results in 92% of the people with VL and it gave correct, negative results in 92% of the people who did not have the disease. The test worked better in India and Nepal than in East Africa. In India and Nepal, it gave correct, positive results in 97% of the people with the disease. In East Africa, it gave correct, positive results in only 85% of the people with the disease.

In 11 of the studies, the InBios rK39 ICT test (Seattle WA, USA) was used; four studies assessed the DiaMed rK39 ICT test (Cressier, Switzerland) and three evaluated other tests. There were no significant differences in diagnostic accuracy between commercial brands. A second RDT, the latex agglutination test gave correct, positive results in 64% of the people with the disease and it gave correct, negative results in 93% of the people without the disease.

Marleen Boelaert, PhD, from Institute of Tropical Medicine (Antwerp, Belgium) and the senior author of the report, said, “The best chance of a cure for VL lies in a correct diagnosis, so utilizing accurate RDTs is of paramount importance. Our review indicates that the rK39 ICT shows higher sensitivity and specificity for the diagnosis of VL in patients with febrile splenomegaly and no previous history of the disease than the latex agglutination test, but the sensitivity is notably lower in East Africa than in the Indian subcontinent. The size of the studies involving the other RDTs lack accuracy, validation, or both.” The report was published on June 20, 2014, in the journal the Cochrane Library.

Related Links:

Liverpool School of Tropical Medicine
InBios
DiaMed




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.